ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02893553
Recruitment Status : Recruiting
First Posted : September 8, 2016
Last Update Posted : January 23, 2018
Sponsor:
Collaborator:
Kessler Foundation
Information provided by (Responsible Party):
Jill M. Wecht, Ed.D., James J. Peters Veterans Affairs Medical Center

Brief Summary:
Dysregulation of blood pressure (BP), secondary to decentralized autonomic nervous system (ANS) control of the cardiovascular system, often results in chronic hypotension and orthostatic hypotension (OH) in persons with spinal cord injury (SCI), particularly in those with high cord lesions (i.e., above T6). While most hypotensive individuals with chronic SCI remain asymptomatic and do not complain of symptoms associated with cerebral hypoperfusion, evidence of reduced resting cerebral blood flow (CBF) has been reported in association with low systemic BP in the SCI and non-SCI populations. Reduced CBF in hypotensive individuals may lead to cognitive dysfunction, and we reported significantly impaired memory and marginally impaired attention processing in hypotensive individuals with SCI compared to a normotensive SCI cohort. Furthermore, we found that CBF was not increased during cognitive testing in individuals with SCI, which may contribute to impaired cognitive function compared to non-SCI controls. Although asymptomatic hypotension may have an adverse impact on cognitive function and quality of quality of life (QOL) clinical management of this condition is extremely low. In fact, we reported that while nearly 40% of Veterans with SCI were hypotensive, less than 1% carried the diagnosis of hypotension or were prescribed an anti-hypotensive medication. The discrepancy between incidence and treatment of asymptomatic hypotension in the SCI population may relate to a paucity of treatment options which are supported by rigorous clinical trials documenting safe and effective use of anti-hypotensive therapy on BP, CBF and cognitive function. We hypothesize these study medications may increase systolic blood pressure to the normal range and improve cerebral blood flow velocity. Results and conclusions will not be removed from the record.

Condition or disease Intervention/treatment Phase
Spinal Cord Injury Autonomic Dysreflexia Baroreceptor Integrity Sympathetic Integrity Vagal Integrity Autonomic Integrity Hypotensive Cognitive Function Cerebral Blood Flow Blood Pressure Drug: Midodrine Hydrochloride Drug: Pyridostigmine Bromide Drug: Mirabegron Other: Placebo Phase 2

Detailed Description:

Study 1: Subjects will visit the laboratory between 3 and 9 times for 4 hours to determine the BP response to each dose of the 3 study medications (midodrine, pyridostigmine, and mirabegron). Upon arrival to the laboratory subjects will be randomized to receive midodrine, pyridostigmine, or mirabegron. Subjects will remain seated in their wheelchair for the duration of testing. Instrumentation will be applied by study personnel while subject is seated quietly, this can take up to 20 minutes. Instrumentation includes placement of 3 ECG electrodes for continuous HR monitoring and finger and brachial BP cuffs. BP, BR and HR will be recorded for 5-minutes before medication administration (baseline). After baseline, a small pill will be given with a glass of water. BP, BR and HR will be monitored for 5-minutes every 30 minutes for 4 hours after drug administration.

Study 2: Twenty will visit the laboratory on 4 occasions to determine the effects of three anti-hypotensive agents, compared to placebo, on BP, CBFv, and cognitive performance on selected neuropsychological tests. Upon arrival to the laboratory for every visit subjects will be randomized to receive midodrine, pyridostigmine, mirabegron, or matching placebo. Neither the study subject nor the investigator will know which is being administered. Subjects will remain seated in their wheelchair throughout the duration of the study session and will be closely monitored by study personnel. Instrumentation will include placement of 3 ECG electrodes for continuous heart rate (HR) monitoring, finger and brachial BP cuffs, and a Doppler ultrasound probe positioned at the left MCA for continuous CBFv monitoring. Subjects will remain quietly seated in their wheelchair for 30-minutes after instrumentation for a 5-minute recording of continuous HR, BP, and CBFv (baseline). Prior to the baseline data collection period, the first battery of cognitive tests will be administered. The study medication will be administered to the subject along with a glass of water approximately 30-minutes after arrival to the laboratory. There will be a 2 hour break period until the second cognitive battery begins.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
Study Start Date : December 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Study 1
Study 1: is a dose escalation to determine the individualized dose of each of 3 medications (midodrine, pyridostigmine, mirabegron) that increases SBP into the normal range (111-139 mmHg). The investigator will be using midodrine hydrochloride, pyridostigmine bromide and mirabegron.
Drug: Midodrine Hydrochloride
study 1 will be single blind. study 2 will be blinded randomized-control trial.
Other Name: midodrine

Drug: Pyridostigmine Bromide
study 1 will be single blind. study 2 will be blinded randomized-control trial.
Other Name: pyridostigmine

Drug: Mirabegron
study 1 will be single blind. study 2 will be blinded randomized-control trial.

Experimental: Study 2
Study2: is a randomized placebo-controlled double-blinded investigation to determine the effect of the normalization of SBP on cerebral blood flow, cognitive function (memory and attention processing) and quality of life. The investigator will be using midodrine hydrochloride, pyridostigmine bromide, mirabegron and placebo.
Drug: Midodrine Hydrochloride
study 1 will be single blind. study 2 will be blinded randomized-control trial.
Other Name: midodrine

Drug: Pyridostigmine Bromide
study 1 will be single blind. study 2 will be blinded randomized-control trial.
Other Name: pyridostigmine

Drug: Mirabegron
study 1 will be single blind. study 2 will be blinded randomized-control trial.

Other: Placebo
placebo will only be used for study arm 2, the randomized blinded phase.




Primary Outcome Measures :
  1. Systolic Blood Pressure [ Time Frame: Up to 5 years ]
    Seated systolic blood pressure following intervention administration.

  2. Cerebral Blood Flow [ Time Frame: Up to 5 years ]
    Middle cerebral artery blood flow velocity following intervention administration compared to placebo.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Spinal Cord Injured

  • Any level of injury
  • Any ASIA grade of SCI
  • Primarily wheelchair dependent for mobility
  • Duration of injury ˃ 1 year

Exclusion Criteria:

  • Current illness or infection
  • History of severe autonomic dysreflexia (AD: condition where BP increases)
  • More than 3 symptomatic events per week; BP elevations above 140/90 mmHg; adverse symptoms reporting (e.g., light headedness, dizziness, goosebumps, chills, nausea, etc.)
  • Diagnosis of hypertension
  • History of Traumatic Brain Injury (TBI)
  • Documented history of traumatic brain injury (TBI)
  • Neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, etc)
  • History of epilepsy or other seizure disorder
  • Liver or kidney disease
  • Bladder problems including blockage of the urine and/or weak urine stream
  • Diagnosis of a psychiatric disorder such as schizophrenia or bipolar disorder
  • Diagnosis of artery disease, heart failure, irregular heartbeat, and AV block
  • Allergies to aspirin, a yellow dye, pyridostigmine bromide, midodrine hydrochloride, lyethylene oxide, polyethylene glycol, hydroxypropyl cellulose, butylated hydroxytoluene, magnesium stearate, hypromellose, yellow ferric oxide, and red ferric oxide
  • Had major surgery in the last 30 days
  • Illicit drug abuse within the last 6 months
  • Pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02893553


Contacts
Contact: Alexander T Lombard, MS 973-324-3588 alombard@kesslerfoundation.org

Locations
United States, New Jersey
Kessler Foundation Research Center Recruiting
West Orange, New Jersey, United States, 07052
Contact: Alexander T Lombard, MS    973-324-3588    alombard@kesslerfoundation.org   
Contact: Caitlyn G Katzelnick, MS    973-324-3588    ckatzelnick@kesslerfoundation.org   
Principal Investigator: Jill M Wecht         
United States, New York
James J Peters VAMC Recruiting
Bronx, New York, United States, 10468
Contact: Matthew T Maher, MS    718-584-9000 ext 3122    Matthew.Maher@va.gov   
Principal Investigator: Jill M Wecht, EdD         
Sponsors and Collaborators
James J. Peters Veterans Affairs Medical Center
Kessler Foundation
Investigators
Principal Investigator: Jill M Wecht, Ed.D James J. Peters VA Medical Center

Responsible Party: Jill M. Wecht, Ed.D., Research Health Scientist, James J. Peters Veterans Affairs Medical Center
ClinicalTrials.gov Identifier: NCT02893553     History of Changes
Other Study ID Numbers: WEC-16-015
First Posted: September 8, 2016    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Antihypertensive Agents
Wounds and Injuries
Spinal Cord Injuries
Hypotension
Autonomic Dysreflexia
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Vascular Diseases
Cardiovascular Diseases
Autonomic Nervous System Diseases
Bromides
Mirabegron
Midodrine
Pyridostigmine Bromide
Anticonvulsants
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Adrenergic alpha-1 Receptor Agonists